Core Viewpoint - Zai Ding Pharmaceutical (09688) has received approval from the National Medical Products Administration (NMPA) for the new drug application of Nemonapride Chloride Capsules (Kai Jie Le), marking a significant breakthrough in the treatment of schizophrenia with a novel mechanism of action, the first in over 70 years [1] Group 1: Company Developments - Zai Ding Pharmaceutical's stock rose over 4% in early trading, currently up 3.45% at HKD 14.1, with a trading volume of HKD 59.19 million [1] - The approval of Nemonapride Chloride Capsules is based on data from Phase I pharmacokinetic studies and Phase III clinical trials conducted in China, as well as three global EMERGENT clinical studies [1] Group 2: Industry Impact - The approval of this new schizophrenia treatment represents a fundamental breakthrough in the field, potentially changing the landscape of schizophrenia therapies [1] - Zai Ding Pharmaceutical acquired exclusive rights to develop, manufacture, and commercialize Nemonapride Chloride Capsules in Greater China from Karuna Therapeutics for USD 187 million in November 2021 [1]
港股异动 | 再鼎医药(09688)早盘涨超4% 重磅抗精神分裂症新药凯捷乐在中国获批上市